Zimbabwe has turned down a significant American healthcare agreement valued at $367m (£272m) over five years over Washington's request for confidential data.
This move was revealed following a government memo from December was leaked, which showed President Emmerson Mnangagwa felt the agreement was "unbalanced".
A government spokesman has since clarified that the United States was requesting genetic material for research and profit while was unwilling to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued talks to secure a agreement acceptable to both sides so the nation's critical HIV treatment initiative can be sustained.
Broader Context
This rejection comes after a similar situation in Kenya, where a court suspended a related deal with the US following concerns were raised about the security of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump stated its spending was "wasteful" and his government was pursuing direct bilateral agreements to enhance transparency and accountability.
Based on statements, 16 nations in Africa have to date agreed to similar health pacts, representing over $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration would have delivered immense benefits for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for scientific discovery without any assurance that the final treatments would be available to our citizens if a new pandemic emerge."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting frameworks previously set up through the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework created to manage future global health emergencies.
"This system is intended to ensure that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how subsequent collaboration might be designed in a way that respects the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the government's concerns, but urged that talks should continue since a large portion of the country's Aids initiatives relied on international support.
"If specific concerns arise, including those relating to information security or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," the group added.
The halted deal highlights the continuing tensions between accepting much-needed international aid and protecting a country's data in an increasingly data-driven world.